Understanding Male Breast Cancer in the Community Setting.Debra Patt, MD, Janet Espirito, PharmD, Brian Turnwald, J. Russell Hoverman, MD, Marcus Neubauer, MD, Thomas Cartwright, MD, Barry Brooks, MD, Leslie Busby, MD, Mark Sitarik, MD, Michael Kolodziej, MD, Aimee Ginsburg, PharmD, Sheetal Sheth, PharmD, Jody Garey, PharmD, Matthew Clayton, Greg Nelson, Roger Anderson, DrPH, Roy Beveridge, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development Team
Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community.Avani Joshi, PhD, Healthcare Informatics, US OncologyDavid Fryefield, MD, Willamette Valley Cancer Institute and Research CenterMichael Forsyth, RPh, MBA, Rocky Mountain Cancer CentersWilliam Lopez, Healthcare Informatics, US Oncology
Demographic and treatment characteristics for advanced basal cell carcinoma (aBCC) in an oncology outpatient setting.Thomas Cartwright, MD, Ocala Oncology CenterMichael Forsyth, RPh, MBA, Rocky Mountain Cancer CentersHeather Hartnett, PhD, Hsingwen Chung, MS, Melissa Halm, MPH, Healthcare Informatics, US Oncology
mCRC - Survival Outcomes with the use of Bevacizumab beyond progression in metastatic colorectal cancer patients.Clara Chen, MS, Healthcare Informatics, US OncologyDebra Patt, MD, MPH, Texas OncologyMichael Forsyth, RPh, MBA, Rocky Mountain Cancer CentersDenise Kazzaz, Jeff Shankleton, Ramachandran Ganesh, Healthcare Informatics, US Oncology
Evaluation of relation between Oncotype DX recurrence score and adjuvant chemotherapy administration.Kavita Sail, MS, PhD, Healthcare Informatics, US OncologyDebra Patt, MD, MPH, Texas OncologyMichael Forsyth, RPh, MBA, Rocky Mountain Cancer CentersMelissa Halm, MPH, William Lopez, Healthcare Informatics, US Oncology
|SOURCE US Oncology, Inc.|
Copyright©2010 PR Newswire.
All rights reserved